A

Ascidian Therapeutics

RNA exon editing for gene therapies

Computational Biology Co-op

Quantitative Biology & BiostatisticsUpdated on Nov 12
Internship · Winter 2027Boston, MA, USANo salary listed

About the Job

Requirements

  • The candidate must currently be enrolled in a Bachelor’s or Master’s degree program in a scientific discipline; Biology, Chemistry, Physics, and Computer Science are welcome fields.
  • The candidate must be available to work full-time for up to six consecutive months beginning in January 2027.
  • The candidate needs beginner experience using the command line on MacOS or Linux.
  • The candidate needs basic to intermediate ability in a scripting language such as Python, R, or Perl.
  • The candidate must work from the Boston, Massachusetts site throughout the Co-op/Intern term.

Responsibilities

  • Analyze next-generation sequencing data and contribute to the computational design of RNA drug candidates while working with an experienced scientific mentor.
  • Process and analyze sequencing data for programs across the company, including running pipelines, interrogating RNA reads, data visualization, and ad-hoc computational tasks.
  • Work independently and collaboratively with multidisciplinary teams to solve complex problems.
  • Maintain detailed records using electronic lab notebooks.
  • Communicate progress and results to the team.

Desired Qualifications

  • Knowledge of computational biology software tools and aligners such as Samtools, BWA, and MiniMap.
  • Molecular biology knowledge focused on RNA processing and expression.

About the Company

Ascidian Therapeutics

RNA exon editing for gene therapies

Ascidian Therapeutics focuses on RNA exon editing to treat diseases. It develops technologies that edit RNA transcripts after they are made from DNA, enabling precise changes while keeping natural gene expression patterns. This approach aims to produce full-length, functional proteins and offer durable therapeutic effects without direct DNA editing or gene replacement. The company monetizes by licensing its RNA exon editing technology to healthcare providers and research institutions and may also participate in development and sale of therapies based on its platform. Compared with competitors, it emphasizes transcriptome re-engineering in human cells to achieve steady gene expression without altering the genome, reducing certain genetic risks while maintaining normal regulatory control. The overall goal is to translate RNA exon editing into accessible therapies for patients by partnering for licensing and therapy development.

Company size
11-50
Company stage
Series A
Total funding
$90M
Headquarters
Boston, MA
Founded
2020

Recently Posted Jobs

Explore more opportunities at Ascidian Therapeutics

See more jobs